Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), filed a Form 4 on September 3, 2026, disclosing transactions in common stock and restricted stock units dated September 1, 2026.

Key Highlights

  • RSU vesting: 8,789 shares of common stock were acquired by Bilinsky upon vesting of restricted stock units on September 1, 2026, at a price of $0.
  • Tax withholding: 4,472 shares were withheld by the issuer to satisfy mandatory tax withholding requirements upon RSU vesting, at a price of $8.28 per share.
  • Post-transaction holdings: Bilinsky directly held 138,237 shares of common stock following the reported transactions.
  • Remaining RSUs: 17,580 restricted stock units remained beneficially owned following the transactions, reflecting the remainder of RSUs granted on March 1, 2024.
  • Vesting schedule: According to the filing, the remaining RSUs will vest in equal quarterly installments.

RSU Vesting and Mandatory Tax Withholding by Iovance Biotherapeutics COO

According to the filing, Igor Bilinsky, identified as Chief Operating Officer of Iovance Biotherapeutics, Inc., reported two transactions in common stock on September 1, 2026. The first was an acquisition of 8,789 shares at $0, representing shares underlying restricted stock units that vested on the transaction date. The second was a disposition of 4,472 shares at $8.28 per share, which the filing describes as shares withheld by the issuer to satisfy mandatory tax withholding requirements upon RSU vesting, noting explicitly that this "is not an open market sale of securities."

Following these transactions, Bilinsky's direct beneficial ownership of common stock stood at 138,237 shares, according to the filing. The filing also discloses activity in Table II covering derivative securities: 8,789 restricted stock units were reported as settled via the "M" transaction code, with 17,580 RSUs remaining. The filing notes that this aggregate figure reflects the remainder of RSUs granted on March 1, 2024, but does not include any other RSUs held by Bilinsky.

The filing was signed by Igor Bilinsky on September 3, 2026, and was made by one reporting person. Each RSU, as described in the filing, represents a contingent right to receive one share of the issuer's common stock.

What Was Disclosed

The Form 4 disclosed the vesting of 8,789 RSUs and the withholding of 4,472 shares for taxes by Iovance Biotherapeutics on behalf of its COO, Igor Bilinsky, on September 1, 2026, leaving him with 138,237 shares and 17,580 RSUs directly held.